Start with cancer, then reuse UniProt Q16832 as the stable protein anchor across project notes and exports.
CHEMBL5122 Target Snapshot
Discoidin domain-containing receptor 2 · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Discoidin domain-containing receptor 2 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q16832. Start with cancer, then reuse UniProt Q16832 as the stable protein anchor across project notes and exports.
Discoidin domain-containing receptor 2 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with cancer because it currently carries approved-linked support. Linked drugs include REGORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDiscoidin domain-containing receptor 2
Review this target as Discoidin domain-containing receptor 2, mapped to UniProt Q16832. Sequence length is 855 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Discoidin domain-containing receptor 2 as ChEMBL target CHEMBL5122, mapped to UniProt Q16832. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Discoidin domain-containing receptor 2 is the right protein anchor across sources, using UniProt Q16832 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Discoidin domain-containing receptor 2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q16832 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Discoidin domain-containing receptor 2 |
| UniProt Accession | Q16832 |
| Component Type | Protein |
| Sequence Length | 855 aa |
Discoidin domain-containing receptor 2
How to read this target
Review this target as Discoidin domain-containing receptor 2, mapped to UniProt Q16832. Sequence length is 855 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Discoidin domain-containing receptor 2 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with cancer because it currently carries approved-linked support. Linked drugs include REGORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5938192 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL5781115 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL5787536 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL5965095 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL5756960 | 9.7 | IC50 | 0.2 | Preclinical |
| CHEMBL5885968 | 9.7 | IC50 | 0.2 | Preclinical |
| CHEMBL6051298 | 9.7 | IC50 | 0.2 | Preclinical |
| CHEMBL6055194 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL6027087 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL6052146 | 9.52 | IC50 | 0.3 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Binding — 380 assays, 425 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 285 | 257 | 7.2 |
| assay format | 54 | 87 | 6.3 |
| cell-based format | 40 | 37 | 6.5 |
| subcellular format | 1 | 44 | 6.2 |
ADME — 3 assays, 8 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 7 | 6.6 |
| cell-based format | 1 | 0 | — |
| single protein format | 1 | 1 | 6.0 |